Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor AgonistsGlobeNewsWire • 09/13/22
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory BoardGlobeNewsWire • 09/07/22
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment ConferenceGlobeNewsWire • 09/06/22
Biora Therapeutics, Inc's (BIOR) CEO Adi Mohanty on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/15/22
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics PlatformGlobeNewsWire • 08/10/22
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 08/08/22
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022GlobeNewsWire • 08/03/22
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022GlobeNewsWire • 07/14/22
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics PlatformGlobeNewsWire • 07/07/22
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices ConferenceGlobeNewsWire • 06/22/22
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative ColitisGlobeNewsWire • 05/31/22
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/16/22
Biora Therapeutics' (BIOR) CEO Adi Mohanty on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/10/22